¼¼°èÀÇ Çǵà¼È ¸¶Ä¿ ½ÃÀå
Fiducial Markers
»óǰÄÚµå : 1766989
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,225,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,675,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Çǵà¼È ¸¶Ä¿ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 6,640¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 2,380¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Çǵà¼È ¸¶Ä¿ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 6,640¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±Ý¼ÓÀº CAGR 5.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 7,620¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æú¸®¸Ó ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,230¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Çǵà¼È ¸¶Ä¿ ½ÃÀåÀº 2024³â¿¡´Â 3,230¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 8.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 3,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.8%¿Í 4.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 3.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è Çǵà¼È ¸¶Ä¿ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ÀÇ·á ¿µ»ó Áø´Ü ¹× ¹æ»ç¼± Ä¡·á¿¡¼­ Çǵà¼È ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Çǵà¼È ¸¶Ä¿´Â ¿µ»ó Áø´Ü ¹× ¹æ»ç¼± Ä¡·áÀÇ Á¤È®¼ºÀ» ³ôÀ̱â À§ÇØ ÀÇ·á ºÐ¾ß, ƯÈ÷ Á¾¾çÇÐ ºÐ¾ß¿¡¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çǵà¼È ¸¶Ä¿´Â Á¾¾ç ³» ¶Ç´Â Á¾¾ç ±Ùó¿¡ ¼³Ä¡µÇ´Â ÀÛÀº ±Ý¼Ó ¶Ç´Â Æú¸®¸Ó ¸¶Ä¿·Î, ü³» Á¾¾çÀÇ Á¤È®ÇÑ À§Ä¡¸¦ ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀ» ÁÖ¸ç, Á¤À§Àû ¹æ»ç¼± Ä¡·á(SBRT), °­µµº¯Á¶ ¹æ»ç¼± Ä¡·á(IMRT) µîÀÇ Ä¡·á¿¡¼­ Àǻ簡 Ÿ°ÙÆÃ Á¤È®µµ¸¦ Çâ»ó½Ãų ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Á¤È®µµ´Â ÁÖº¯ °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÁÙ¿© ºÎÀÛ¿ëÀ» ÁÙÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾Ï ȯÀÚ°¡ Áõ°¡ÇÏ´Â °¡¿îµ¥, Çǵà¼È ¸¶Ä¿´Â Àü¸³¼±¾Ï, Æó¾Ï, °£¾Ï µî ´Ù¾çÇÑ Á¾·ùÀÇ ¾Ï¿¡ Á¤È®ÇÑ ¹æ»ç¼±·®À» Á¶»çÇϱâ À§ÇØ ³ôÀº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù.

Çǵà¼È ¸¶Ä¿´Â ¹æ»ç¼± Ä¡·á ¿Ü¿¡µµ CT, MRI, ÃÊÀ½ÆÄ µîÀÇ ¿µ»ó Áø´Ü ±â¼ú¿¡µµ »ç¿ëµÇ¸ç, ÃÖ¼Òħ½À ¼ö¼úÀ̳ª »ý°Ë ½Ã Á¾¾ç ¹× ±âŸ ±¸Á¶¹°À» ½Ã°¢È­ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó Ä¡·á¸¦ ¸ÂÃãÈ­ÇÏ´Â Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °ÍÀº Çǵà¼È ¸¶Ä¿ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ̸ç, ƯÈ÷ ºÏ¹Ì¿Í À¯·´°ú °°ÀÌ ÀÇ·á ÀÎÇÁ¶ó°¡ ¹ß´ÞÇÑ Áö¿ª¿¡¼­´Â Á¤È®¼º°ú ÃÖ¼Òħ½ÀÀû ±â¼úÀÌ ¿ì¼±½ÃµÇ°í ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀÌ Çǵà¼È ¸¶Ä¿ °³¹ß¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

Àç·á °úÇаú ¸¶Ä¿ µðÀÚÀÎÀÇ ±â¼úÀû Áøº¸·Î ÀÎÇØ Çǵà¼È ¸¶Ä¿ÀÇ ¾ÈÀü¼º, °¡½Ã¼º ¹× »ýüÀûÇÕ¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±Ý, ¹é±Ý, »ýºÐÇØ¼º Æú¸®¸ÓÀÇ »ç¿ëÀ» Æ÷ÇÔÇÑ ¸¶Ä¿ Àç·áÀÇ Çõ½ÅÀº Çǵà¼È ¸¶Ä¿ÀÇ Ã¼³» ¾ÈÁ¤¼º°ú ÀûÇÕ¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î, ±Ý ¸¶Ä¿´Â À̹ÌÁö ½ºÄµ¿¡¼­ ³ôÀº °¡½Ã¼ºÀ» Á¦°øÇÏ´Â µ¿½Ã¿¡ ºñ¹ÝÀÀ¼ºÀ̸ç ȯÀÚ¿¡°Ô ¾ÈÀüÇϱ⠶§¹®¿¡ Àå±âÀûÀΠü³» »ðÀÔ¿¡ ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ ¼­¼­È÷ ¿ëÇØµÇ´Â »ýºÐÇØ¼º ¸¶Ä¿´Â ¿Ü°úÀû Á¦°ÅÀÇ Çʿ伺À» ÁÙ¿© ȯÀÚÀÇ Æí¾ÈÇÔ°ú ÆíÀǼºÀ» Çâ»ó½Ãŵ´Ï´Ù.

Ç︮Äà ¸¶Ä¿ ¹× ¸ÖƼ ºÎ¹® ¸¶Ä¿¿Í °°Àº ÷´Ü µðÀÚÀÎÀº ¿¬Á¶Á÷ ³» °íÁ¤¼ºÀ» Çâ»ó½Ã۰í, À̵¿À» ¹æÁöÇϸç, Á¤È®ÇÑ Å¸°ÙÆÃÀ» À§ÇÑ ¾ÈÁ¤ÀûÀÎ ¹èÄ¡¸¦ º¸ÀåÇÕ´Ï´Ù. ¸¶Ä¿´Â ¶ÇÇÑ MRI À¯µµÇÏ Ä¡·á¸¦ ¹Þ´Â ȯÀÚ¸¦ À§ÇÑ MRI ÀûÇÕ¼º ¸¶Ä¿¿Í °°ÀÌ Æ¯Á¤ ¿µ»ó ¾ç½Ä¿¡ ÀûÇÕÇϵµ·Ï ¼³°èµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¹ßÀüÀ¸·Î ÀÎÇØ Çǵà¼È ¸¶Ä¿ÀÇ Àû¿ë ¹üÀ§°¡ È®´ëµÇ¾î ȯÀÚÀÇ ¾ÈÀü°ú Æí¾ÈÇÔÀ» Çâ»ó½ÃŰ¸é¼­ Ä¡·á ¹× ¿µ»ó Áø´ÜÀÇ Á¤È®¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á¿Í ÃÖ¼Òħ½ÀÀÇ Æ®·»µå°¡ Çǵà¼È ¸¶Ä¿ ½ÃÀå Çü¼º¿¡ ¾î¶² ¿ªÇÒÀ» Çϰí Àִ°¡?

Á¤¹ÐÀÇ·á¿Í ÃÖ¼Òħ½À Ä¡·á·ÎÀÇ ÀüȯÀº Çǵà¼È ¸¶Ä¿¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº Á¤È®¼º°ú °³ÀÎÈ­µÈ Ä¡·á¿¡ ÁßÁ¡À» µÎ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. Çǵà¼È ¸¶Ä¿´Â Á¾¾çÀÇ À§Ä¡¸¦ ÆÄ¾ÇÇÏ°í ½Ç½Ã°£ ¿µ»ó °¡ÀÌ´ø½º¸¦ Áö¿øÇÏ´Â Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. À̴ ǥÀû Ä¡·á¸¦ Á¦°øÇϰí ÃÖ¼Òħ½ÀÀû Ä¡·á·Î ÁÁÀº °á°ú¸¦ ¾ò±â À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Àü¸³¼±¾Ï Ä¡·á¿¡¼­ Çǵà¼È ¸¶Ä¿´Â Á¤È®ÇÑ ¹æ»ç¼± Á¶»ç°¡ °¡´ÉÇÏ¿© ÀÎÁ¢ Àå±âÀÇ ¼Õ»ó À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ÃÖ¼Òħ½À ¼ö¼úÀº Á¢±Ù Æ÷ÀÎÆ®°¡ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ Á¤È®ÇÑ ½Ã°¢È­¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Çǵà¼È ¸¶Ä¿¸¦ »ç¿ëÇÔÀ¸·Î½á ¿Ü°úÀÇ»ç¿Í ¹æ»ç¼±»ç´Â ÀÌ·¯ÇÑ ½Ã¼ú Áß ³ôÀº Á¤È®µµ¸¦ À¯ÁöÇÏ¿© ¼º°ø·üÀ» ³ôÀ̰í ȸº¹ ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Á¤È®¼ºÀ» ¿ì¼±½ÃÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϴ ȯÀÚ Á᫐ Áø·á¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Â °¡¿îµ¥, Çǵà¼È ¸¶Ä¿´Â Ä¡·á¿Í Áø´Ü ¸ðµÎ¿¡¼­ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

Çǵà¼È ¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Çǵà¼È ¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, Á¤¹Ð ¿µ»ó ¹× ¹æ»ç¼± Ä¡·áÀÇ ¹ßÀü, ÃÖ¼Òħ½ÀÀû ±â¼úÀÇ Ã¤ÅÃ, ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¿¡ ±âÀÎÇÕ´Ï´Ù. Àü¸³¼±¾Ï, Æó¾Ï, °£¾Ï µîÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çǵà¼È ¸¶Ä¿´Â Ä¡·áÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÁÖº¯ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, MRI ÀûÇÕ¼º ¹× »ýºÐÇØ¼º ¿É¼Ç°ú °°Àº ¸¶Ä¿ÀÇ ¼ÒÀç ¹× µðÀÚÀÎ Çõ½ÅÀº ´Ù¾çÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ Àû¿ëÀ» È®´ëÇÏ¿© Ä¡·áÀÇ È¿°ú¿Í È¿À²À» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Ä¡·á¹ý¿¡ Àû¿ëÀ» È®´ëÇÏ¿© È¿°ú¿Í ȯÀÚ °æÇèÀ» ¸ðµÎ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

Á¤¹ÐÀÇ·á¿Í ÃÖ¼Òħ½ÀÀû Ä¡·áÀÇ ¹ßÀüÀº ½Ç½Ã°£ À̹Ì¡°ú ÀÌ·¯ÇÑ Á¢±Ù¹ý¿¡¼­ Ç¥Àû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â Çǵà¼È ¸¶Ä¿°¡ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÷´Ü ¾Ï Ä¡·á¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ Àνİú ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Çǵà¼È ¸¶Ä¿´Â °³ÀÎÈ­µÇ°í Á¤È®¼º¿¡ ÃÊÁ¡À» ¸ÂÃá ÇコÄɾî Àü·«¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¾Ï ¹ßº´·ü Áõ°¡, ±â¼ú ¹ßÀü, Á¤¹ÐÀÇ·á, ÃÖ¼Òħ½ÀÀû Ä¡·áÀÇ Ãß¼¼ µî ´Ù¾çÇÑ ¿äÀεéÀÌ °áÇÕÇÏ¿© Çǵà¼È ¸¶Ä¿ ½ÃÀåÀÇ °­·ÂÇÑ ¼ºÀåÀ» ÃËÁøÇϰí, Çö´ë ÀÇÇп¡¼­ Ä¡·áÀÇ Á¤È®¼º°ú ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(±Ý¼Ó, Æú¸®¸Ó, ±âŸ Á¦Ç° À¯Çü), ¸ð´Þ¸®Æ¼(CT/CBCT, MRI, ÃÊÀ½ÆÄ, ¹æ»ç¼± Ä¡·á), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¹× ¿Ü·¡ ȯÀÚ ½Ã¼³, µ¶¸³ ¹æ»ç¼± Ä¡·á ¼¾ÅÍ, ¾Ï ¿¬±¸ ¼¾ÅÍ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fiducial Markers Market to Reach US$166.4 Million by 2030

The global market for Fiducial Markers estimated at US$123.8 Million in the year 2024, is expected to reach US$166.4 Million by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Metal, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$76.2 Million by the end of the analysis period. Growth in the Polymer segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$32.3 Million While China is Forecast to Grow at 8.0% CAGR

The Fiducial Markers market in the U.S. is estimated at US$32.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$37.8 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Fiducial Markers Market - Key Trends & Drivers Summarized

What Is Driving Demand for Fiducial Markers in Medical Imaging and Radiation Therapy?

The demand for fiducial markers is increasing in the medical field, particularly in oncology, as they enhance precision in imaging and radiation therapy. Fiducial markers, often small metal or polymer markers placed in or near tumors, help define the exact location of a tumor within the body, enabling doctors to improve targeting accuracy in treatments like stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT). This precision reduces damage to surrounding healthy tissues, resulting in fewer side effects and improved patient outcomes. As cancer cases rise globally, fiducial markers are in high demand for accurately delivering radiation doses to various cancer types, such as prostate, lung, and liver cancers.

In addition to radiotherapy, fiducial markers are also used in diagnostic imaging techniques like CT, MRI, and ultrasound to help visualize tumors and other structures during minimally invasive surgeries and biopsy procedures. The growing focus on precision medicine, which tailors treatment to individual patient needs, is a major driver of the fiducial markers market, particularly in regions with advanced healthcare infrastructure, such as North America and Europe, where accuracy and minimally invasive techniques are prioritized.

How Are Technological Advancements Impacting the Development of Fiducial Markers?

Technological advancements in materials science and marker design are enhancing the safety, visibility, and biocompatibility of fiducial markers. Innovations in marker materials, including the use of gold, platinum, and biodegradable polymers, improve the stability and compatibility of fiducial markers within the body. Gold markers, for instance, offer high visibility on imaging scans while remaining non-reactive and safe for patients, making them suitable for long-term placement. Additionally, biodegradable markers that gradually dissolve reduce the need for surgical removal, enhancing patient comfort and convenience.

Advanced designs, such as helical and multi-segment markers, improve fixation within soft tissues, preventing migration and ensuring stable placement for accurate targeting. Markers are also being designed for compatibility with specific imaging modalities, such as MRI-compatible markers for patients undergoing MRI-guided treatments. These technological advancements are expanding the application of fiducial markers, improving the accuracy of treatment and imaging while enhancing patient safety and comfort.

What Role Do Precision Medicine and Minimally Invasive Trends Play in Shaping the Fiducial Markers Market?

The shift toward precision medicine and minimally invasive procedures is driving demand for fiducial markers, as these approaches emphasize accuracy and personalized treatment. Fiducial markers play a crucial role in localizing tumors and supporting real-time imaging guidance, which is essential for delivering targeted therapies and achieving favorable outcomes in minimally invasive procedures. For instance, in prostate cancer treatments, fiducial markers allow for precise radiation targeting, reducing the risk of damaging adjacent organs.

Minimally invasive procedures rely heavily on accurate visualization, as they involve limited access points. Fiducial markers enable surgeons and radiologists to maintain high levels of precision during these procedures, improving success rates and reducing recovery times. As healthcare systems focus on patient-centric care that prioritizes accuracy and minimizes side effects, fiducial markers are becoming indispensable tools in both therapeutic and diagnostic settings.

What Factors Are Driving Growth in the Fiducial Markers Market?

The growth in the fiducial markers market is driven by the rise in cancer prevalence, advancements in precision imaging and radiotherapy, the adoption of minimally invasive techniques, and the demand for personalized treatment. As the incidence of cancers such as prostate, lung, and liver cancers increases, fiducial markers play a critical role in improving the accuracy of treatment and minimizing damage to surrounding tissues. Innovations in marker materials and designs, including MRI-compatible and biodegradable options, have expanded their application in various treatment modalities, enhancing both effectiveness and patient experience.

The move toward precision medicine and minimally invasive procedures is also driving growth, as fiducial markers enable real-time imaging and targeted treatment in these approaches. With increasing awareness and investment in advanced cancer treatments globally, fiducial markers are becoming essential components of personalized and precision-focused healthcare strategies. Together, these factors-rising cancer rates, technological advancements, precision medicine, and minimally invasive trends-are propelling robust growth in the fiducial markers market, supporting its role in improving treatment accuracy and patient outcomes in modern medicine.

SCOPE OF STUDY:

The report analyzes the Fiducial Markers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Metal, Polymer, Other Product Types); Modality (CT / CBCT, MRI, Ultrasound, Radiotherapy); End-Use (Hospitals & Outpatient Facilities, Independent Radiotherapy Centers, Cancer Research Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â